Pargyline
From Wikipedia, the free encyclopedia
| This article or section needs sources or references that appear in reliable, third-party publications. Primary sources and sources affiliated with the subject of the article are generally not sufficient for a Wikipedia article. Please include more appropriate citations from reliable sources, or discuss the issue on the talk page. This article has been tagged since December 2007. |
|
Pargyline
|
|
| Systematic (IUPAC) name | |
| N-Benzyl-N-methyl-prop-2-yn-1-amine | |
| Identifiers | |
| CAS number | |
| ATC code | C02 C02LL01 |
| PubChem | |
| Chemical data | |
| Formula | C11H13N |
| Mol. mass | 195.69 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pargyline is a monoamine oxidase B (MAO-B) inhibitor. It functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.[1]
[edit] References
- ^ Tulane University School of Medicine Department of Pharmacology: Autonomic Drug Profile handout, October 2006
|
|||||||||||||||||||||||||||||||

